CareDx, Inc. (CDNA): Price and Financial Metrics

CareDx, Inc. (CDNA): $13.97

0.10 (-0.71%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

B

CDNA Price/Volume Stats

Current price $13.97 52-week high $17.03
Prev. close $14.07 52-week low $4.80
Day low $13.48 Volume 736,900
Day high $14.17 Avg. volume 884,617
50-day MA $12.11 Dividend yield N/A
200-day MA $9.76 Market Cap 727.61M

CDNA Stock Price Chart Interactive Chart >


CareDx, Inc. (CDNA) Company Bio


CareDx, Inc. focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in North America, Europe, the Middle East, Africa, and Latin America. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is based in Brisbane, California.


CDNA Latest News Stream


Event/Time News Detail
Loading, please wait...

CDNA Latest Social Stream


Loading social stream, please wait...

View Full CDNA Social Stream

Latest CDNA News From Around the Web

Below are the latest news stories about CAREDX INC that investors may wish to consider to help them evaluate CDNA as an investment opportunity.

CareDx Joins Forces with the National Foundation for Transplants to Improve Post-Transplant Medication Adherence

BRISBANE, Calif., December 19, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is joining forces with the National Foundation for Transplants (NFT) in offering its Transplant Pharmacy services to NFT patient members to help them manage the complexity of post-transplant medication adherence.

Yahoo | December 19, 2023

How Much Upside is Left in CareDx (CDNA)? Wall Street Analysts Think 26.72%

The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | December 8, 2023

Can CareDx (CDNA) Climb 29.79% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for CareDx (CDNA) points to a 29.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 22, 2023

CareDx, Inc (NASDAQ:CDNA) Q3 2023 Earnings Call Transcript

CareDx, Inc (NASDAQ:CDNA) Q3 2023 Earnings Call Transcript November 8, 2023 CareDx, Inc beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.38. Operator: Good day, everyone, and welcome to today’s CareDx Inc. Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity […]

Yahoo | November 10, 2023

CareDx Reports Third Quarter 2023 Results

BRISBANE, Calif., November 08, 2023--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today reported financial results for the third quarter ended September 30, 2023.

Yahoo | November 8, 2023

Read More 'CDNA' Stories Here

CDNA Price Returns

1-mo -7.67%
3-mo 46.44%
6-mo 16.90%
1-year 73.11%
3-year -84.78%
5-year -63.27%
YTD 16.42%
2023 5.17%
2022 -74.91%
2021 -37.23%
2020 235.88%
2019 -14.20%

Continue Researching CDNA

Want to see what other sources are saying about CareDx Inc's financials and stock price? Try the links below:

CareDx Inc (CDNA) Stock Price | Nasdaq
CareDx Inc (CDNA) Stock Quote, History and News - Yahoo Finance
CareDx Inc (CDNA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!